Answers are grounded in this paper and cite their sources.
) will probably be developed in the future to decide whether a prostate biopsy should be obtained. mpMRI has a good specificity for detecting T3 stage cancers, but its sensitivity is low. It should therefore not be used routinely for staging purposes in low-risk patients. Nomograms combining mpMRI findings and other clinical and biochemical data will also probably be used in the future to better assess the risk of T3 stage disease.
No takes yet. Share an insight, caveat, or question.
Rouvière et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: